Outcome of therapy-related myeloid neoplasms treated with azacitidine. by Fianchi, L et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Fianchi et al. Journal of Hematology & Oncology 2012, 5:44
http://www.jhoonline.org/content/5/1/44RESEARCH Open AccessOutcome of therapy-related myeloid neoplasms
treated with azacitidine
Luana Fianchi1, Marianna Criscuolo1, Monia Lunghi2, Gianluca Gaidano2, Massimo Breccia3, Alessandro Levis4,
Carlo Finelli5, Valeria Santini6, Pellegrino Musto7, Esther N Oliva8, Pietro Leoni9, Antonietta Aloe Spiriti10,
Francesco D’Alò1, Stefan Hohaus1, Livio Pagano1, Giuseppe Leone1 and Maria Teresa Voso1*Abstract
Background: Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid
leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high
levels of DNA methylation.
Methods: We retrospectively evaluated 50 t-MN patients (34 MDS and 16 AML) selected among all patients
receiving azacitidine (AZA) at 10 Italian Hematology Centers. Patients had developed a t-MN at a median of
6.5 years (range 1.7- 29) after treatment of the primary tumor (hematological neoplasm, 27 patients; solid tumor,
23 patients).
Results: The overall response rate was 42% (complete remission: 10 patients, partial remission: 2 and
hematological improvement: 8 patients) and was obtained after a median of 3 cycles (range 1–6). Median
overall survival (OS) was 21 months (range 1–53.6+) from AZA start. OS was significantly better in patients with
less than 20% blasts, in normal karyotype t-AML and when AZA was used as front-line treatment. This was
confirmed by the multivariate analysis.
Conclusions: This study reports efficacy of AZA in the largest series of therapy-related MN patients treated with
5-AZA. Our data show that blasts and karyotype maintain their important prognostic role in t-MN also in the
azacitidine era.
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Therapy-related myeloid neoplasms (t-MN) have been
recognized as a clinical and biological distinct entity in
the 2008 WHO AML classification [1]. By definition,
these diseases occur after cytotoxic treatment for a
primary cancer or after immunosuppressive treatment.
t-MN account for about 10% of all AML, and may
arise from few months to several years after the pri-
mary tumor, depending on type of cytotoxic treatment,
cumulative dose and dose-intensity [2,3]. At disease
onset, t-MN typically present with unfavorable features,
such as peripheral blood cytopenias, complex karyo-
type, and chromosome 11, 5 or 7 abnormalities [4-6].* Correspondence: mtvoso@rm.unicatt.it
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reproduction in any medium, provided the orIncreased rates of gene-specific hypermethylation have
been reported in t-MN [6-9].
Because performance status is often poor, mostly due
to age, primary tumor and exposition to prior therap-
ies, the use of standard chemotherapy protocols is gen-
erally impaired in these patients. Treatment varies
from supportive care to conventional chemotherapy
and allogeneic HSCT, but outcome remains dismal.
Even in aggressively treated cases, complete remission
rates are usually lower and remission duration is
shorter than in de novo MDS/AML, with median sur-
vival rates of less than one year in most studies [5,10-13].
Allogeneic HSCT is the only curative option, but it is
not feasible in the majority of patients and is often
complicated by high transplantation-related mortality
rates [10]. Response rates similar to de novo AML have
been recently obtained only for t-AML patients carryingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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protocols [5].
During the last few years, hypomethylating agents have
been largely used in the treatment of intermediate-2 and
high risk MDS [14]. Azacitidine has been shown to be
effective also in unfavorable patient sub-groups, inducing
response rates up to 60% and improving survival com-
pared to conventional care [14-16].
Here we report that azacitidine treatment might rep-
resent a safe and effective option in t-MN patients,
given the biological and clinical characteristic of the
disease and the potentially fatal consequences of more
aggressive therapies.
Methods
Patients and methods
In this multicenter study, we retrospectively collected
clinical data of patients diagnosed with t-MN and trea-
ted with azacitidine (AZA, VidazaTM, Celgene Corp.) at
10 Italian Hematology Centers. Fifty cases of t-MN con-
secutively treated with AZA were identified and analyzed
among all patients with MDS or AML receiving AZA at
the participating centers between October 2005 and Au-
gust 2011. Criteria for AZA treatment were: diagnosis of
t-MN according to the WHO classification, defined as
leukemias occurring in patients with a history of prior
cytotoxic treatment for a primary tumor. Further criteria
were adequate renal and hepatic function, and absence
of uncontrolled infections. Patients gave written
informed consent to treatment and to the collection of
clinical data, in accordance with the Declaration of Hel-
sinki and institutional guidelines.
AZA was started at a median of 1.8 months (range 0–
29) from t-MN diagnosis, at the conventional dose of
75 mg/m2 daily for 7 days (36 patients, 72%), or at a
fixed dose of 100 mg daily for 5, 7 or 10 days (3, 7 and 4
patients, respectively) every 4 weeks. A median of 4
cycles (range 1–23) were administered, with 37.7% of
patients receiving 4 or more cycles.
AZA was administered until disease progression, un-
acceptable toxicity, or patient decision to withdraw
consent. Response was assessed according to the
modified International Working Group (IWG-2006)
criteria [17,18]. We evaluated overall response (OR),
including complete remission (CR), partial remission
(PR) and hematological improvement (HI) rates, and
overall survival.
Adverse events were graded according to the National
Cancer Institute Common Toxicity Criteria (CTC-NCI,
version 4.0).
Statistical analysis
Associations between patient characteristics were ana-
lyzed using the Fisher’s exact test. Overall survival wascalculated from start of AZA treatment to date of death
from any cause or of the last follow-up. Survival curves
were estimated using the Kaplan-Meier product limits
method. Log-rank test was applied to study survival dif-
ferences according to patient characteristics. Age (≤ 65
vs >65 y.o.), primary malignancy (hematological vs solid),
comorbidity index (HCT-CI) (19), AZA dose (75 mg/
m2/7 days vs 100 mg/day 10 days vs 100 mg/day 5 or
7 days), WHO diagnosis (RCMD vs RAEB 1/2 vs AML),
karyotype (normal vs abnormal), chromosome 7 abnor-
malities, transfusion dependence, previous treatment (no
vs ESA vs hydroxyurea or chemotherapy) were evaluated
in the univariate analysis. Cox proportional hazard
model was also used for multivariate analysis of factors
with prognostic significance in the univariate analysis
(blast count >20%; karyotype, previous cytotoxic treat-
ment for t-MDS/AML). Computations were performed
using the Stata 10.0 software (Stata Corp., College Sta-
tion, TX). All tests were two-sided with α= 0.05.
Results
Patient characteristics
The main patient characteristics at diagnosis are reported
in Table 1. There were 28 males and 22 females, with a
median age of 66 years (range 37–84). According to the
WHO classification, there were 34 MDS (12 RCMD, 9
RAEB1 and 13 RAEB2) and 16 AML.
All patients had previously received chemotherapy (27
patients, 52%), radiotherapy (9 patients, 17%) or a com-
bination of both (14 patients, 27%) for their primary
malignancy.
The primary malignancy was a hematological neo-
plasm in 27 cases (54%), and a solid tumor in 23 cases
(46%). t-MN occurred at a median of 6.1 years (range
0.2 - 29.8 years) from treatment of the primary malig-
nancy (Table 1).
Karyotype was evaluable in 47 patients and was nor-
mal in 17 (34%), complex (3 or more aberrations) in 20
(43%), and with a single chromosome abnormality in 10
cases (20%). Deletion or monosomy of chromosome 7
was present as single alteration or in the context of a
complex karyotype in 14 patients (30%).
Twenty-six patients (52%) were transfusion-dependent
before AZA start [median 2 units of red blood cells
(range 1–10) /month and median 5 units of platelets
/month (range 1–12)]. Four patients had previously
received erythropoietin, and 6 patients had previously
been treated with hydroxyurea or standard AML induc-
tion therapy, while in 40 patients AZA was used as
front-line treatment.
Treatment response and overall survival
Treatment response was evaluated in 48 patients (35
MDS and 13 AML) after a median of 3 cycles of AZA
Table 1 Clinical characteristics of 50 patients with t-MN
treated with azacitidine
Patient Characteristics n (range)
Median age (years, median, range) 66 (37–84)
Sex (M/F) 28/22
ECOG PS
0–1 46
2-3 4
Type of t-MDS/AML according to the WHO
- AML: 16
BM-blasts 20-29% 5
BM-blasts ≥30% 11
- MDS: 34
RCMD 12
RAEB1 9
RAEB 2 13
Primary malignancy :
- Lymphoproliferative disease 19
- Multiple myeloma 3
- Chronic myeloproliferative disease 5
- Breast cancer 6
- Urogenital 9
- Other 8
Treatment for Primary Malignancy:
- Chemotherapy 27
- Radiotherapy 9
- RTx + CTx 14
Median latency between primary cytotoxic
therapy and t-MN diagnosis (years)
6.1 (0.2-29.8)
Median value at diagnosis (range):
- White blood cell counts (109 /L) 2.6 (0.1-26)
- Platelets (109 /L) 69.5 (5–395)
- Bone Marrow blasts (%) 13 (1–90)
- LDH (UI/L) 403 (130–2498)
Median interval between t-MN diagnosis
and AZA treatment (months)
1.8 (0–39)
Response to treatment:
- Overall response: 20 (42%)
- CR 10 (21%)
- PR 2 (4.2%)
- HI 8 (16.7%)
- Stable disease 15 (31%)
- Progression 13 (27%)
- Not evaluable 2
Median cycles number for response 3 (range 1–6)
Legend: RTx: Radiotherapy ; CTx: Chemotherapy; CR: complete remission; PR:
partial remission; HI: hematological improvement.
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interrupted treatment on patient’s request (1 patients
with stable disease) and due to severe constipation (1
patient). (Table 1). The overall response rate (ORR) was
42%, with complete remission in 10 patients (21%), par-
tial remission in 2 (4.2%) and hematological improve-
ment in 8 patients (16.7%). The disease was stable in 15
patients (31%), while 13 patients (27%) presented disease
progression at a median of 4 AZA cycles (range 3–7).
Treatment was generally well tolerated. Sixteen patients
(32%) experienced grade 3 or 4 myelosuppression in-
cluding neutropenia (8 patients), thrombocytopenia and
neutropenia (7 patients) or anemia (1 patient). Eight
patients (16%) developed an infection (pneumonia in 7
patients and sepsis in 1), that was the cause of death in
2 cases (4%). Other grade 3 or 4 non hematological ad-
verse events consisted of erythema at the injection site
in 2 cases and constipation in 2 cases.
Median duration of response was 7 months (range 3-
47+). Five patients (10%), 4 resistant to AZA, underwent
allogeneic stem cell transplantation following azacitidine.
Notably, 5 patients (10%) presented a relapse of the
primary malignancy (1 non-Hodgkin lymphoma, 2
breast cancers, 1 bladder cancer and 1 cancer of the
uterus) after a median of 4 cycles of AZA (range 2–
10), and at a median of 13 years from the diagnosis
of the primary malignancy (range 9–26 years). None
of the patients died as a consequence of these
relapses, but they were resistant to AZA and died due
to t-MN progression.
Median overall survival of t-MN patients was
25.6 months (range 1.1-61.1+) from diagnosis and
21 months (range 1–53.6+) from azacitidine start
(Figure 1). Survival was 72% (95 C.I.: 53-82%) at the
median follow up of 8.7 months (range 1–54).
By stratifying patients according to t-MN type (below
or over 20% bone marrow blasts), the overall response
rate appeared to be higher in t-MDS versus t-AML, al-
beit the difference was not statistically significant (50%
vs 21%, p = 0.1). Overall survival from initial t-MN
diagnosis or from AZA start was significantly better in
t-MDS versus t-AML (40.4 months versus 19.4 months
from initial diagnosis, p: 0.005, and 30.9 months versus
8.5 months, from AZA start, p: 0.0045, Figure 2). This
significant difference in overall survival was confirmed
also when stratifying patients according to WHO cat-
egories (RCMD versus RAEB1-2 versus AML, p = 0.02)
(Figure 3).
Concerning significant prognostic factors for survival,
aberrant karyotype confirmed its negative value in
t-AML (median survival: 8.3 vs 17 months in normal
karyotype, p = 0.045), but not in t-MDS (median survival:
21.9 vs 42.3 months, p = 0.57, Figure 3). Survival was su-
perior in patients who received AZA as front-line
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Figure 1 Overall survival of 50 t-MN patients treated with azacitidine. Median survival was 25.6 months (range 1.1-61.1+) from initial
diagnosis and 21 months (range 1–53.6+) from AZA start.
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cytotoxic drugs to treat t-MN prior to AZA (p = 0.0001,
Table 2). No survival differences were observed when
stratifying patients according to the type of previous0.
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Figure 2 t-AML patients had a significantly worse survival than
t-MDS patients. A) Median survival was 8.5 months in t-AML versus
30.9 months in t-MDS (p = 0.0045), classified according to the WHO
classification (over 20% bone marrow blasts as definition for AML)
B) In t-MDS, there were no survival differences when stratifying for
WHO subtypes (RCMD vs RAEB1-2).malignancy, time between treatment of the primary ma-
lignancy and development of t-MN, time between t-MN
diagnosis and AZA start, comorbidity index (HCT-CI)
[19] peripheral blood counts, IPSS score in MDS,0.
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Figure 3 Aberrant karyotype was predictor of death in t-AML,
but not in t-MDS patients. Survival was studied according to the
presence of any cytogenetic aberrations versus normal karyotype.
Table 2 Prognostic factors for overall survival
Patients
(n)
Number of
responders}
Median OS
(months)
p
Age
≤ 65 years 24 10 21.9 0.85
> 65 years 26 10 24.5
Primary Malignancy
Hematological 27 12 11.67 0.83
Solid 23 8 17.97
azacitidine dose
75 mg/smq/7 days 36 12 16.7 0.31
100 mg/day 10 days 4 3 14.2
100 mg/day 5 or 7 days 10 5 16.2
WHO diagnosis
RCMD 12 9 30.9
RAEB 1/2 22 7 16.8 0.02
AML 16 4 8.5
Karyotype
Normal 8 8 27.7
Single or double abnormality 9 3 11.6 0.66*
Complex 20 9 16.2
Chromosome 7 abnormalities
Yes 14 8 11.63 0.72
No 33 12 17.96
Transfusion dependence
Yes 26 10 11.6 0.38
No 24 10 21.9
Previous Treatment
No pre-treatment 40 17 27.7 0.0001
ESA 4 2 16.2
Hydroxyurea 2 1 9.5
Conventional Chemotherapy 4 0 5.4
HCT-CI #
0–2 5 0 8.8
3 19 6 8.5 0.2
4 6 4 53.7
>5 9 4 16.2
* The difference in overall survival between normal and aberrant karyotype
was however statistically significant restricting the analysis to t-AML patients
(Figure 3A).
} Number of patients achieving CR, PR or HI; # HCT-CI data were available for
39 patients.
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Hazard Ratio p 95%C.I.
WHO type (t-AML vs t-MDS) 3.49 0.03 1.17-10.46
Karyotype (aberrant versus normal) 2.2 0.015 0.75-6.58
Front-line AZA (no vs yes) 3.45 0.08 0.87-13.62transfusion-dependence or AZA dose (Table 2). The
multivariate analysis confirmed the significant negative
prognostic value of bone marrow blast over 20%, and
karyotype (Table 3).
Discussion
Prognosis of patients with therapy-related myeloid neo-
plasms treated with conventional chemotherapy is poor,
with lower remission rates and shorter remissionduration than in de novo AML. Furthermore, t-MN dis-
play high levels of DNA methylation [6-9] and high fre-
quency of monosomal karyotype, including complete or
partial deletions of chromosome 5 or 7 [5,10,20].
The biological features and the unsatisfactory results
of standard chemotherapy provided the rationale for our
retrospective study on the role of azacitidine in t-MN.
We observed 42% overall response rate and a median
overall survival of 21 months. The outcome of our
AZA-treated t-MN patients is similar to results obtained
in de novo high-risk MDS treated with AZA at standard
doses [14,21] and also favorably compares to conven-
tional therapy in t-MN [10,12]. In a recently published
study by Kayser et al.. on 200 selected t-AML patients
included in 6 prospective German-Austrian multi-center
trials, complete response to standard induction therapy
was 63% in t-AML, with a median overall survival of
about 15 months [5]. There are only few data on AZA
efficacy in t-MN. Seventy-four t-MDS were included in a
large cohort of 282 high-risk MDS treated with AZA
[15]. ORR was 43% for the whole patient cohort, but
therapy-related forms had a shorter survival (median
9.2 months versus 15.3 months in de novo MDS,
p = 0.002) [15].
In our study, AZA efficacy was particularly evident in
t-MDS, who had a significantly better overall survival
than t-AML patients. This was true also considering
WHO subgroups, with significantly different overall sur-
vival in refractory cytopenia with multilineage dysplasia
(RCMD), versus RAEB-1 and −2, versus AML. These
data, confirm the role of WHO subgroups in therapy-
related as in de novo-MDS [22,23].
Although karyotype maintains its prognostic value in
t-AML, survival of t-AML patients within the same cyto-
genetic risk group is generally shorter than that of
patients with de novo AML [24]. Karyotype prognostic
groups differ between MDS and AML. Due to the lim-
ited number of patients, especially those with a favorable
karyotype, we grouped patients according to the type of
t-MN and presence of any chromosomal abnormalities.
As a result, our t-AML patients with aberrant karyotype
(including chromosome 7 alterations in 30% of cases)
had a significantly shorter survival than patients with a
normal karyotype. Also, patients treated with AZA
front-line had a significantly better outcome than
patients who received previous cytotoxic drugs to treat
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blast counts below 15% and no previous treatment with
low-dose cytosine-arabinoside independently predicted
better response to AZA in higher risk MDS [15]. It is
also possible that patients treated with cytoreductive
chemotherapy had a more aggressive t-MN disease, and
thus were less likely to respond to azacitidine when used
in second line.
In our series 5 patients had a chronic myeloprolifera-
tive disease as previous neoplasm. The inclusion of these
disorders into the list of primary malignancies is debated
due to possibility that the AML transformation might
represent a natural evolution of disease. The exposure to
cytotoxic agents however could hasten or induce this
transformation as also suggested by an increased risk of
AML in patients who were treated with radioactive
phosphorus or chlorambucil in the Polycytemia Vera
Study Group trial [25].
Five of fifty patients had a relapse of the previous ma-
lignancy during treatment with AZA after a median of 4
cycles, and at a median of 13 years from the diagnosis of
the primary malignancy. This observation should be at
least a warning to include re-evaluation and monitoring
of disease activity of the primary malignancy in future
studies on t-MN treatment. There are only very limited
data in the literature. More than 20 years ago, Carr et al.
reported a higher incidence of testicular tumors after
prolonged treatment with AZA in a rat model with an
already high spontaneous tumor rate [26]. Itzykson et al
did not report any relapse of the primary tumor in
74 t-MDS patients treated with a median of six AZA
cycles [15]. On the other hand, AZA efficacy has been
reported in solid tumors and lymphoproliferative dis-
eases [27,28]. Our group has recently reported a patient
with Hodgkin lymphoma and a t-MDS, who achieved
complete response of MDS and HL following AZA
treatment [29].
In conclusion, our data indicate effectiveness of up-
front AZA in t-MN, and are particularly encouraging in
the setting of t-MDS. Blasts and karyotype maintain
their important prognostic role for t-MN also in the aza-
citidine era. As there is no accepted standard treatment
for patients with t-MN, other treatment approaches in
the same time period of our study varied from support-
ive care only to low-dose cytarabine, gemtuzumab-
ozogamicin in combination with G-CSF and cytarabine,
standard induction chemotherapy and front-line allogen-
eic bone marrow transplantation [30]. Only about 25%
of t-MN patients registered in 4 of the participating cen-
ters were treated with azacitidine. These data will help
to design prospective studies for t-MN to address effi-
cacy and risks of AZA treatment, in particular as a less
toxic “bridging” therapy to a curative treatment ap-
proach as allogeneic transplantation.Competing interests
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